Home › Companies › CAMP

Camp4 Therapeutics

Market cap $251M 62.8M shares (10-Q, Nov 4, 2026) × $4.00 close Nov 17, 2026

Most recent annual filing: 2026-03-05

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. CMP-002 trial start4Q 2026CMP-002 trial start, 4Q 2026, material
  2. CMP-002 enrollment done2027CMP-002 enrollment done, 2027, notable
  3. SHANK3 corporate update2027SHANK3 corporate update, 2027, routine
  4. Zorevunersen Stoke Ph3 topline3Q 2027Zorevunersen Stoke Ph3 topline, 3Q 2027, material
  5. CMP-002 topline1H 2028CMP-002 topline, 1H 2028, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Technology platforms

RAP Platform

Regulatory RNA Amplification Platform — maps regulatory RNAs (regRNAs) and generates ASO therapeutic candidates targeting regRNAs associated with haploinsufficient and recessive partial loss-of-function genetic disorders; disease focus spans more than 1,200 such disorders where modest protein upregulation may be clinically meaningful.

Targets: regRNAs, regRNA

RAP Platform · GSK

Regulatory RNA-targeting ASO platform that maps regulatory RNAs (regRNAs) acting on transcription factors to identify therapeutic candidates designed to upregulate gene expression in haploinsufficient and recessive partial loss-of-function genetic disorders; disease focus includes neurodegenerative and kidney disease indications via GSK collaboration.

Targets: regRNAs

RAP Platform · GlaxoSmithKline

Proprietary regRNA mapping and ASO discovery platform that identifies and characterizes regulatory RNAs controlling protein-coding genes, enabling design of ASO therapeutics to upregulate gene expression. Primary focus on CNS haploinsufficient diseases; also being extended to neurodegenerative, kidney, liver, heart, skeletal muscle, and immune system disease areas via collaboration with GSK.

RAP Platform · GlaxoSmithKline Intellectual Property (No. 3) Limited

RNA-regulating therapeutic platform used to identify and develop product candidates for a broad range of genetic diseases. Used as the basis for the GSK collaboration and license agreement.

Discontinued (1)

Capital (as filed)

Cash
$125M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$8.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$125M cash, runway through the end of 2028 per the deep dive of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Camp4 Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch CAMP4 Therapeutics (CAMP) - Scientific Deep Dive for CMP-002 and Pipeline Products CAMP4 has a genuinely novel upregulation platform in an unmet disease but zero human data, no issued patents, no US sites, no PD biomarker, and the nearest class precedent just failed Phase 3; at $4.06 the stock prices roughly fair odds on a 2028 coin flip.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (22)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)